TREVI THERAPEUTICS INC (TRVI) Stock Income Statement
NASDAQ:TRVI - Nasdaq - US89532M1018 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 50.80M | 51.52M | 33.92M | 29.91M | 32.48M | |||
| Research and Development | 38.38M | 39.38M | 23.68M | 19.83M | 22.98M | |||
| Selling, General, and Administrative Expenses | 12.71M | 12.15M | 10.24M | 10.07M | 9.49M | |||
| Operating Income | -50.80M | -51.52M | -33.92M | -29.91M | -32.48M | |||
| Interest Income/Expense | 3.73M | 3.60M | 4.36M | 430.00K | -1.11M | |||
| Other Income/Expense | -25.00K | -15.00K | 469.00K | 290.00K | -380.00K | |||
| Income Before Taxes | -47.02M | -47.94M | -29.10M | -29.19M | -33.96M | |||
| Income Tax | -36.00K | -30.00K | -32.00K | -40.00K | -20.00K | |||
| Net Income | -47.00M | -47.91M | -29.07M | -29.15M | -33.94M | |||
| EBITDA | -50.66M | -51.38M | -33.80M | -29.87M | -32.43M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.45 | -0.47 | -0.29 | -0.45 | -1.49 | |||
| Non GAAP EPS | -0.45 | -0.47 | -0.29 | -0.56 | -1.52 | |||
| Statistics | ||||||||
All data in USD